Clinical

Dataset Information

Concordance study between Guardant360 and RASKET-B(MEBGEN) of RAS/BRAF evaluation in colorectal cancer. (GOZILA additional study).


ABSTRACT: Primary outcome(s): Overall percent agreement (OPA), positive percent agreement (PPA), and negative percent agreement (NPA) of RAS mutations by Guardant360 in comparison with those assessed by RASKET-B. OPA, PPA, NPA of BRAF V600E mutations by Guardant360 in comparison with those assessed by RASKET-B.

DISEASE(S): Patients With Unresectable Advanced/recurrent Colorectal Cancers

PROVIDER: 2724283 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR